INTRODUCTION: Nephropathy in HIV-infected patients has been associated with progression to AIDS and death. The virus, several comorbid conditions and certain medications may contribute to the development and progression of kidney disease. METHODS: This study analyzed data collected from HIV-infected persons enrolled in a HIV registry in Puerto Rico during January 1998 through September 2006. Demographic factors, clinical manifestations, laboratory findings at enrollment, and antiretroviral therapy (ART) prescriptions were compared between patients with and without kidney disease. Death status and cause of death by December 2006 were also evaluated and compared. RESULTS: The study included 1,283 subjects, 69.0% male, 39.7% injecting drug users, 19.5% hepatitis C infected, 6.5% with diabetes mellitus (DM-2), 11.6% had hypertension (HTN) and 9.0% had kidney disease. Patients with kidney disease had significantly higher (P < .05) HIV viral load mean (273,499 vs. 202,858 copies/mL), CD4 T-cell count < 200 (57.0% vs. 44.4%), underweight (22.9% vs. 10.9%), DM-2 (13.9% vs. 5.8%), HTN (27.8% vs 10.0%) and mortality (15.9 vs 5.7 deaths per 100 years of follow-up) than those without it. Cox proportional hazard analysis showed that patients with kidney disease had a higher mortality risk (2.1) after controlling for age, sex, HIV risk factor, ART prescription in the last year and HIV disease duration. CONCLUSIONS: This study demonstrated a substantial disparity in mortality for Puerto Rican HIV-infected patients with nephropathy. Kidney disease preventive strategies that include aggressive control of HIV-infection and chronic medical conditions, such as hypertension and diabetes, are recommend as an approach to reduce this health disparity.
INTRODUCTION:Nephropathy in HIV-infectedpatients has been associated with progression to AIDS and death. The virus, several comorbid conditions and certain medications may contribute to the development and progression of kidney disease. METHODS: This study analyzed data collected from HIV-infectedpersons enrolled in a HIV registry in Puerto Rico during January 1998 through September 2006. Demographic factors, clinical manifestations, laboratory findings at enrollment, and antiretroviral therapy (ART) prescriptions were compared between patients with and without kidney disease. Death status and cause of death by December 2006 were also evaluated and compared. RESULTS: The study included 1,283 subjects, 69.0% male, 39.7% injecting drug users, 19.5% hepatitis C infected, 6.5% with diabetes mellitus (DM-2), 11.6% had hypertension (HTN) and 9.0% had kidney disease. Patients with kidney disease had significantly higher (P < .05) HIV viral load mean (273,499 vs. 202,858 copies/mL), CD4 T-cell count < 200 (57.0% vs. 44.4%), underweight (22.9% vs. 10.9%), DM-2 (13.9% vs. 5.8%), HTN (27.8% vs 10.0%) and mortality (15.9 vs 5.7 deaths per 100 years of follow-up) than those without it. Cox proportional hazard analysis showed that patients with kidney disease had a higher mortality risk (2.1) after controlling for age, sex, HIV risk factor, ART prescription in the last year and HIV disease duration. CONCLUSIONS: This study demonstrated a substantial disparity in mortality for Puerto Rican HIV-infectedpatients with nephropathy. Kidney disease preventive strategies that include aggressive control of HIV-infection and chronic medical conditions, such as hypertension and diabetes, are recommend as an approach to reduce this health disparity.
Authors: Samir K Gupta; Joseph A Eustace; Jonathan A Winston; Ivy I Boydstun; Tejinder S Ahuja; Rudolph A Rodriguez; Karen T Tashima; Michelle Roland; Nora Franceschini; Frank J Palella; Jeffrey L Lennox; Paul E Klotman; Sharon A Nachman; Stephen D Hall; Lynda A Szczech Journal: Clin Infect Dis Date: 2005-04-22 Impact factor: 9.079
Authors: Lynda Anne Szczech; Donald R Hoover; Joseph G Feldman; Mardge H Cohen; Stephen J Gange; Lisa Goozé; Nancy R Rubin; Mary A Young; Xiaotao Cai; Qiuhu Shi; Wei Gao; Kathryn Anastos Journal: Clin Infect Dis Date: 2004-09-27 Impact factor: 9.079
Authors: Lynda Anne Szczech; Samir K Gupta; Ramez Habash; Antonio Guasch; Robert Kalayjian; Richard Appel; Timothy A Fields; Laura P Svetkey; Katherine H Flanagan; Paul E Klotman; Jonathan A Winston Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Lytt I Gardner; Scott D Holmberg; John M Williamson; Lynda A Szczech; Charles C J Carpenter; Anne M Rompalo; Paula Schuman; Robert S Klein Journal: J Acquir Immune Defic Syndr Date: 2003-02-01 Impact factor: 3.731
Authors: Gregory M Lucas; Joseph A Eustace; Stephen Sozio; Evelyn K Mentari; Kofi A Appiah; Richard D Moore Journal: AIDS Date: 2004-02-20 Impact factor: 4.177
Authors: Andy I Choi; Rudolph A Rodriguez; Peter Bacchetti; Daniel Bertenthal; Paul A Volberding; Ann M O'Hare Journal: J Am Soc Nephrol Date: 2007-10-17 Impact factor: 10.121
Authors: Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian Journal: Clin Infect Dis Date: 2014-09-17 Impact factor: 9.079
Authors: Brittany A Shelton; Gideon Berdahl; Deirdre Sawinski; Benjamin P Linas; Peter P Reese; Margaux N Mustian; Rhiannon D Reed; Paul A MacLennan; Jayme E Locke Journal: Am J Transplant Date: 2019-01-25 Impact factor: 9.369
Authors: Udeme E Ekrikpo; Andre P Kengne; Aminu K Bello; Emmanuel E Effa; Jean Jacques Noubiap; Babatunde L Salako; Brian L Rayner; Giuseppe Remuzzi; Ikechi G Okpechi Journal: PLoS One Date: 2018-04-16 Impact factor: 3.240
Authors: Carlos E Rodríguez-Díaz; Edda I Santiago-Rodríguez; Gerardo G Jovet-Toledo; Jorge Santana-Bagur; Yemile Ron-Suarez; Juan C Orengo; Felipe Arbelaez; Homero Monsanto Journal: HIV AIDS (Auckl) Date: 2019-07-24